Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Calidi Biotherapeutics ( (CLDI) ) has shared an update.
Calidi Biotherapeutics, a leader in targeted antitumor virotherapies, has announced significant strides in its clinical programs and financial positioning. The company received FDA clearance for its NeuroNova (CLD-101) program targeting high-grade glioma and showcased its RTNova (CLD-400) platform at major conferences. Additionally, Calidi raised $2 million through a direct offering and private placement, despite reporting a net loss for Q3 2024.
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.